This medication is used in the therapeutic management of conditions requiring a reduction in stomach acid production to achieve symptom control. Gastro is indicated to address typical symptoms of heartburn and acid regurgitation, providing relief from discomfort that can interfere with daily life. It is utilized in the treatment plan for chronic conditions such as gastroesophageal reflux disease (GERD) and is part of the established approach for specific types of erosive esophagitis and peptic ulcers. The benefit of use is focused on supporting the healing process of affected tissues and the long-term maintenance of symptom relief.

---

Quick Fact: Relief for Persistent Acid Symptoms and Ulcer Management

---

Who can and cannot use Gastro?

The population eligibility for Gastro (Famotidine) is strictly defined by regulatory documents, outlining who may use the medicine and under what conditions.

Contraindications establish absolute non-eligibility. Gastro must not be used by patients with known hypersensitivity to Famotidine or to any other H2-receptor antagonist, due to the risk of cross-sensitivity. Additionally, use is contraindicated in women who are breastfeeding, as the medicine is known to be excreted into human breast milk.

Age and Physiological Restrictions

The medicine is generally approved for adults and pediatric patients aged 1 to 16 years for specific indications. Use is not recommended in infants under 1 year of age, as safety and efficacy are not established in this group.

Eligibility is restricted for patients with moderate to severe renal impairment (kidney disease). Use in this population requires a modification of the therapeutic regimen, as standard use can lead to drug accumulation. While use is permitted during pregnancy, it is generally not recommended unless considered essential by the physician, owing to limited human data.

Interactions with Other Medicines and Products

The interaction profile for Gastro (Famotidine) is formally documented as primarily pharmacokinetic, driven by its impact on gastric acidity and its metabolic clearance pathways. This medicine is a gastric acid secretion inhibitor, and its principal interaction pattern involves Gastric pH-Dependent Drug Absorption.

Key Documented Interactions

Interaction Type	Interacting Substance/Condition	Regulatory Outcome
Reduced Exposure	Drugs requiring acidic gastric pH (e.g., Ketoconazole, Atazanavir)	Co-administration may significantly reduce the systemic exposure and potential efficacy of the co-administered drug.
Increased Exposure	Tizanidine (CYP1A2 Substrate)	Risk of substantially increased Tizanidine blood concentrations, linked to increased adverse event risk.
Population-Specific Risk	Renal Impairment	Significantly increased systemic exposure of Famotidine itself due to reduced renal clearance, which increases the risk of CNS adverse reactions.

Co-administration with antacids is documented to slightly decrease Famotidine's bioavailability, but this effect is officially classified as not clinically significant, and no mandatory separation time is required. Furthermore, the official prescribing information states the medicine may be taken with or without food, as this interaction is also not considered clinically significant.

How Gastro Works

The mechanism of action involves the compound binding to the Ca^2+-sensing receptor ( CaSR) on the chief cells of the parathyroid gland. This allosteric binding increases the sensitivity of the receptor to extracellular calcium. The resulting activation of the receptor initiates a cascade that inhibits the synthesis and release of parathyroid hormone ( PTH). The decreased PTH secretion subsequently changes serum calcium concentration. This process modulates osteoclast activity, which leads to altered bone remodeling rates. Furthermore, the compound decreases parathyroid cell proliferation. The overall effect is the modulation of calcium homeostasis via PTH suppression and secondary effects on bone turnover and parathyroid tissue dynamics. The compound exhibits selectivity for the CaSR and accumulates within parathyroid tissue to exert its primary effect.

How Gastro (Famotidine) is Used in Clinical Practice

Gastro (Famotidine) is administered using specific, labeled protocols that define the route, frequency, and duration of use. The medicine is available for both the oral route as tablets and an oral suspension, and for the intravenous (IV) route as an injection solution. The IV form is typically reserved for short-term use in hospital settings when oral administration is not feasible.

Standard Administration Patterns

Administration frequency and timing depend on the condition being addressed. For acute peptic ulcer treatment, the typical adult dose is often 40 mg once daily at bedtime, or 20 mg administered twice daily. For long-term prevention of ulcer recurrence, the prescribed use is generally 20 mg once daily. Conditions such as symptomatic Gastroesophageal Reflux Disease (GERD) require a regimen of 20 mg or 40 mg taken twice daily.

Oral doses may be taken with or without food. If using the oral suspension, the container should be shaken vigorously prior to use. Due to potential absorption effects, Famotidine should be administered 1 to 2 hours before taking antacids.

Duration and Adjustments

Treatment follows time-bound protocols: acute courses for ulcers or GERD typically last between 6 to 12 weeks. Extended use, such as for ulcer recurrence prevention, may continue for up to 1 year. Dosage adjustment is officially mandated for adult patients with moderate to severe renal impairment (creatinine clearance < 60 mL/min), often requiring a reduction to 50% of the usual dose or an extension of the dosing interval to 36 to 48 hours.

Research Evidence / Overview of Studies for Gastro (Famotidine)

The research evidence for Famotidine comes primarily from Randomized Controlled Trials (RCTs) and systematic reviews that focus on measurable outcomes like the resolution of tissue damage and the reported severity of physical discomfort. This overview describes the research framework without offering any interpretation of specific results or clinical guidance.

---

Evidence for Healing and Preventing Ulcers

This section summarizes the findings from clinical research that studied the medicine's role in the management of both duodenal and gastric ulcers. These studies specifically examined how ulcer lesions changed over short periods of time and how patient-reported experiences evolved.

Research Focus on Ulcer Healing Rates

The primary body of evidence for ulcer management is composed of short-term, double-blind RCTs that compared the medicine to a placebo (an inactive substance) or other treatments explored in the research. Researchers monitored adult patients with ulcers confirmed by an internal examination called an endoscopy. The main outcome measured was the endoscopic healing rate, which is the percentage of patients whose ulcers showed resolution after a defined study period, typically between four and eight weeks.

Studies used in research exploring how symptoms change over time also monitored patient-reported outcomes describing perceived discomfort, such as the time to change in pain scores. These trials reported measurements of healing and symptomatic changes during the course of the short-term study period.

Research Focus on Preventing Ulcer Recurrence

Maintenance studies, which are long-term RCTs, were applied in research contexts involving fluctuating or unstable symptoms to observe patterns of ulcer recurrence after they had initially healed. The outcomes monitored included the incidence of ulcer recurrence—meaning the rate at which ulcers returned over extended follow-up periods, typically up to 12 months. Studies were monitored for periods of heightened symptom activity, and the reported findings describe patterns observed in the studies related to recurrence rates.

---

Evidence for Managing Gastroesophageal Reflux Disease (GERD) and Heartburn

Research for acid reflux disease includes placebo-controlled trials applied in studies examining patient-reported experiences of symptoms such as heartburn and acid regurgitation. This evidence base includes distinct studies for symptomatic conditions and those involving tissue damage.

Short-term RCTs were used in research exploring short-term symptom changes in adults with symptomatic non-erosive GERD. These studies measured outcomes related to physical discomfort using symptom severity scores and patient-reported outcomes. For erosive esophagitis (EE), which involves tissue damage, studies also monitored the endoscopic healing rate of the erosions over periods of up to 12 weeks. Findings described patterns observed in the studies regarding both the resolution of tissue damage and the measured change in symptoms.

---

Long-Term Data and Follow-Up in Studies

Research has explored various follow-up durations across the different indications. For active ulcer healing, follow-up durations were limited, usually running concurrently with the short treatment course of 4 to 8 weeks. In contrast, research exploring ulcer prevention utilized follow-up periods that extended up to 12 months.

Overall, long-term effects are not fully established beyond the typical one-year maintenance trials. Comparative evidence exploring the sustained patterns of use versus other acid-suppressing agents over many years is generally lacking. Studies contribute to the broader evidence landscape but data for certain groups remain insufficient when considering chronic, uninterrupted use over a lifetime.

Common questions about Gastro (FAQ)

Q: What is Gastro and what is it used for?

A: Gastro is a medication containing the active ingredient omeprazole. It belongs to a class of drugs called Proton Pump Inhibitors (PPIs). It is primarily used to decrease the amount of acid produced in the stomach. This helps treat conditions like gastroesophageal reflux disease (GERD), peptic ulcers, and certain conditions where the stomach produces too much acid, such as Zollinger-Ellison syndrome.

---

Q: How should I take Gastro?

A: Gastro is usually taken once a day in the morning, approximately 30 minutes before a meal. The tablet or capsule should be swallowed whole with a glass of water. It is important not to crush, break, or chew the medication. Follow the specific dosing instructions given by your healthcare provider.

---

Q: What are the possible side effects of Gastro?

A: Common side effects can include headache, diarrhea, constipation, stomach pain, and gas. These are typically mild and go away as your body adjusts. Less common but more serious side effects can include severe diarrhea, signs of a kidney problem (like changes in how much you urinate), or symptoms of low magnesium. If you experience severe or persistent side effects, contact your healthcare provider.

How to Store and Dispose of Famotidine (Gastro)

Famotidine must be stored according to regulatory requirements to ensure its stability. Tablets and suspension must be kept at controlled room temperature, typically 20 C to 25 C. Protection is required from excessive heat and moisture. The medicine must remain in its original container and be kept tightly closed.

The medication must always be stored out of the sight and reach of children.

For disposal, unused or expired Famotidine should not be flushed down a toilet or sink. The preferred method is to utilize an authorized drug take-back program. If a program is unavailable, mix the medicine with an undesirable substance, place it in a sealed container, and discard it in the household trash.